Q-omics provides the consensus-scored RBM20 profile across patient tissues and cancer cell-line models. RBM20 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RBM20 is differentially expressed in 16, with the highest sampling consensus in UCEC. Additionally, RBM20 RNA expression shows 18,162 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, UCEC, and TGCT as cancer lineages where RBM20 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RBM20 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RBM20 survival associations across molecular data types. RBM20 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RBM20 RNA expression–survival associations across cancer types. High RBM20 expression shows unfavorable associations in LGG and MESO, but favorable associations in KIRC, SKCM, SCLC and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RBM20 RNA expression.
This table summarizes RBM20 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for RBM20. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RBM20 shows lower tumor expression in UCEC, HNSC, COAD, THCA and BLCA and higher tumor expression in KIRC. The UCEC box plot shows higher RBM20 RNA expression in normal versus tumor tissue (log2 FC = −1.245, t-test p < 0.001).
This table shows molecular features associated with RBM20 in patient tissues and cancer cell lines. In patient samples, RBM20 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RBM20 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and LARGE_INTESTINE.
